The aim of this work was to optimize the prognosis of early recurrences of uterine cancer by searching for informative laboratory biomarkers. The study included 343 patients with I-IV stages FIGO endometrial adenocarcinoma the ages of 53 and 76 years. In patients before surgery, as well as 3 and 6 months after the end of primary treatment, the concentration of oncological markers CA-125, HE4, DJ-1, DKK-1 was determined in blood serum by ELISA and electrochemiluminescence immunoassay. We analyzed the predictive informativeness of monitoring markers to assess the risk of early recurrences of cancer within two years after surgery. In patients with uterine cancer with the stage of the disease and the degree of tumor differentiation in the blood serum, the concentration of DJ-1 is changed. With myometrial invasion of more than 50%, increased serum levels of three markers - CA-125, HE4, and DJ-1. Depending on the risk of disease recurrence, the assessment of which was determined by intraoperative and histological characteristics, a difference was revealed in the content of HE4 and DJ-1 markers in the blood. It was found that the risk of early recurrence of uterine cancer increased (p<0,05) when the concentration of CA-125 exceeded the level of 29,3 U/ml, HE4 was above 79,3 pmol/l, DJ-1 was above 90,0 ng/ml and DKK-1 above 47,3 pg/ml 6 months after the end of primary treatment. The highest predictive information value was found for monitoring DJ-1 and HE4 in blood serum, which indicates that they are promising for use in continuous monitoring of the course of cancer.

No abstract

Objective. To evaluate the diagnostic informativeness of determining the concentration of the MCM5 proliferation marker in the uterine aspirate for the detection of uterine body cancer (UBC) and the differential identifiation of the risk group for patients with suspected non-endometrioid endometrial cancer.Materials and methods. 104 patients diagnosed with UBC and 32 healthy patients of the control group were examined. According to the histological type, 79 (76 %) patients had endometrial cancer, 16 (15 %) had serous and 9 (9 %) clear cell cancer. Endometrial aspiration biopsy was obtained by Pipel biopsy using a two-channel Pipelle catheter. Direct quantitative determination of the concentration of MCM5 in the uterine aspirate cell homogenate was carried out by enzyme-linked immunosorbent assay using specifi MCM5 ELISA test systems.Results. It was found that when the concentration of MCM5 in the uterine aspirate exceeds 11.38 pg/ml, the detection of early-stage UBC is possible with a diagnostic sensitivity of 96.12 % and a specifiity of 78.79 %. When the concentration of MCM5 in the uterine aspirate exceeds 56.9 pg/ml, the relative risk of detecting rare forms of UBC increases (p < 0.0001) by 59.7 times.Conclusions. Determination of the concentration of the protein of the minichromosomal protection family MCM5 in the aspirate of the uterine cavity is informative for the early detection of UBC.